Infectious viral outbreaks such as SARS, MERS, H1N1, Zika, and the current ongoing severe acute respiratory syndrome-related Coronavirus COVID-19 have significantly impacted the health and safety of communities around the world. The continuing outbreak of the SARS-CoV-2 virus has sparked the global research community to rapidly develop potential vaccines and antiviral therapeutics to aid in the prevention, reduce viral replication, or enhance immune response.
Types of Coronaviruses
Coronaviruses (CoVs) get their name from the Latin word “corona” which means “crown”, after the Spike protein (S) found on the surface of the virus. There are four common coronaviruses that commonly circulate in humans and are responsible for cold-like symptoms: HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1. Three other CoVs have emerged as infectious agents, jumping from their normal animal host species to humans: SARS-CoV, MERS-CoV and most recently, SARS-CoV-2 (1).
Why are Leading Virology Labs Working with Nexcelom to Drive the Development of Modern Viral Assays?
Development of Modern Virology Assays
In the past few years, Nexcelom Bioscience has worked with leading labs in the field of virology from government agencies, academic labs, and pharmaceutical companies such as the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID). These labs have developed modern virology assays utilizing plate imagers to increase sensitivity, efficiency, and accuracy which has led to a reduction of materials used and reduction in time to answer critical questions.
Our dedicated field application scientists provide support for the development of new and novel high-throughput image cytometry assays for vaccines and antiviral therapeutics investigation.